These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24201100)

  • 21. Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy.
    Nicosia L; Bucpapaj R; Barresi V; Damante R; Napoli G; Ghimenton C; Giaj-Levra N; Cancedda M; Flaminio S; Figlia V; Alongi F
    Neurochirurgie; 2021 Apr; 67(2):193-197. PubMed ID: 33190809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
    Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
    J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone therapy in advanced prostate cancer.
    Forster TH; Stoffel F; Gasser TC
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract]   [Full Text] [Related]  

  • 26. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Zerbib M; Payan C
    Urology; 1996 Oct; 48(4):661-3. PubMed ID: 8886082
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer.
    Tsutsui T; Miyashita K; Sabit H; Fukui I; Hayashi Y; Mizokami A; Ikeda H; Nagatani H; Nakada M
    World Neurosurg; 2016 Jul; 91():670.e1-6. PubMed ID: 27046016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Kaku H; Tsushima T; Nasu Y; Kumon H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
    [No Abstract]   [Full Text] [Related]  

  • 29. Intermittent versus continuous androgen deprivation in prostate cancer.
    Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
    N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
    J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
    Sakura M; Tsukamoto T; Yonese J; Nakaishi M; Maezawa T; Takimoto K; Fukui I
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):529-32. PubMed ID: 12795169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Endocrine therapy for prostate cancer in the future].
    Usami M
    Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
    J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H; Hinotsu S; Usami M; Arai Y; Kanetake H; Naito S; Hirao Y;
    Cancer; 2009 Aug; 115(15):3437-45. PubMed ID: 19536889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
    Marks LS
    Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.